ClinicalTrials.gg
CompletedNCT03206918Updated Oct 26, 2024Results posted

Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Phase 2 interventional study of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia and Relapsed or Refractory Small Lymphocytic Lymphoma, sponsored by BeiGene. Completed at 11 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.

Primary conditionLeukemia, Lymphocytic, Chronic, B-CellRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Lymphocytic, Chronic, B-Cell
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Leukemia, Lymphocytic, Chronic, B-Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2017, registered Jun 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
91
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing zanubrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 17 under way, 3 of them phase 3. zanubrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
10th of 22
91 · median 71
Started
2017
with 1 other
Phase 2
15 of 22
9 open now
Registered
1st of 22
by date
Lead sponsor
5 of 22
BeiGene

Among the 22 studies testing zanubrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 10th largest by enrollment, is one of 2 that started in 2017, is one of 15 in phase 2, and was the 1st registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

11 of the 22 studies testing zanubrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About zanubrutinib

zanubrutinib: first FDA approval 2019 (BRUKINSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing zanubrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This was a single-arm, open-label, multi-center Phase 2 study in participants with histologically documented CLL/SLL who have relapsed after or refractory to ≥ 1 prior treatment regimen(s). The study is composed of an initial screening phase, a single-arm treatment phase, and a follow-up phase.

03

Conditions studied

  • Relapsed or Refractory Chronic Lymphocytic Leukemia
  • Relapsed or Refractory Small Lymphocytic Lymphoma

Browse trials for

Keywords

  • Bruton's tyrosine kinase
  • Chronic lymphocytic leukemia
  • Relapsed/refractory
  • Zanubrutinib
04

In context

Leukemia, Lymphocytic, Chronic, B-Cell Reclassified

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

This study's enrollment of 91 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Compared within Leukemia, Lymphocytic, Chronic, B-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Confirmed diagnosis with at least one criterion for treatment according to International workshop on chronic lymphocytic leukemia (IWCLL)
  2. (ECOG) performance status of 0-2
  3. by contrast enhanced computerized tomography / magnetic resonance imaging (CT/MRI).
  4. Previously treated with a minimum of 1 prior line of standard chemotherapy-containing regimen (with completion of ≥2 treatment cycles).
  5. Documented failure to achieve at least partial response (PR) or documented disease progression after response to the most recent treatment regimen. disease is defined as treatment failure (stable disease, non-response, progressive disease [PD]) or disease progression within 6 months after the most recent prior therapy (Hallek et al, 2008).
  6. Neutrophils ≥ 0.75 x 109/L independent of growth factor support within 7 days of study entry
  7. ≥ 50 x 109/L, independent of growth factor support or transfusion within 7 days of study entry
  8. of ≥ 30 ml/min (as estimated by the Cockcroft-Gault equation or estimated [eGFR] from the Modification of Diet in Renal Disease [MDRD])
  9. (AST) and alanine aminotransferase (ALT) ≤3 x
  10. ≤2 x ULN (unless documented Gilbert's syndrome)
  11. (INR) ≤1.5 and activated partial thromboplastin time (APTT) ≤1.5 x ULN.
  12. Participants may be enrolled who relapse after stem cell transplant if they are at least 6 months after transplant.
  13. of >4 months
  14. Echocardiogram (ECHO) must demonstrate (LVEF) ≥50%; (AHA, 2016)

Key Exclusion Criteria:

  1. Current or history of central nervous system (CNS) lymphoma
  2. Prior exposure to a Bruton's tyrosine kinase (BTK) inhibitor
  3. Prior given in excess of prednisone 10 mg/day or its equivalent with antineoplastic intent within 7 days.
  4. Major surgery within 4 weeks of screening
  5. Not recovered from toxicity of any prior anti-cancer therapy to \<Grade 1 (except for alopecia, (ANC) and platelets.
  6. History of other active within 2 years of study entry, with exception of (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally (surgery or other modality) with curative intent
  7. Currently active cardiovascular disease
  8. >480 msecs based on Fridericia's formula or other significant abnormalities including second degree atrioventricular (AV) block Type II, or third degree AV block
  9. Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
  10. Active infection including infections requiring oral or intravenous anti-microbials
  11. Known (HIV), or active or infection (detected positive by polymerase chain reaction [PCR]).
  12. Has received allogenic hematopoietic stem cell transplantation prior to enrollment
  13. Any life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the participants's safety, or put the study at risk
  14. Requires ongoing treatment with any medication which is a strong cytochrome P450, family 3, subfamily A () inhibitor or strong CYP3A inducer
  15. Known or clinically suspected Richter's transformation at the time of study entry
  16. History of stroke or intracranial hemorrhage within 6 months prior to enrollment

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    Zanubrutinib

    Drug: Zanubrutinib

Interventions

  • Zanubrutinib 160 mg (two - 80 mg white opaque capsules) taken by mouth (PO) twice a day (BID)

    Also known as: BGB-3111

07

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) by Independent Review Committee (IRC)

    ORR is defined as the number of participants who achieve a best response of CR or, CRi, Nodular Partial Response, PR, and PR with Lymphocytosis as assessed by IRC per the modified IWCLL Guidelines in participants with CLL and the Revised Criteria for Response for Malignant Lymphoma in participants with SLL.

    Time frame: Up to 1 year and 4 months

Secondary outcomes

  1. Progression-free Survival (PFS): Percentage of Participants Progression/Death Event Free

    PFS is defined as the time from treatment initiation to first documentation of progression by International workshop on chronic lymphocytic leukemia (IWCLL) criteria/revised criteria for response for malignant lymphoma or death, whichever is earlier.

    Time frame: 6, 12, 24, and 36 months

  2. Duration of Response (DOR): Event Free Rate - Percentage of Participants Who Remained Event Free

    DOR is defined as the time from the date that response criteria are first met to the date that progressive disease (PD) is objectively documented or death, whichever occurs first

    Time frame: 6, 12, 24, and 36 months

  3. Time to Response (TTR)

    TTR is defined as the time from treatment initiation to first signs of response

    Time frame: Up to 3.5 years

  4. Overall Response Rate as Determined by the Investigator

    Overall response was defined as achieving a best overall response of CR, CRi, nodular partial response (nPR), PR, or partial response with lymphocytosis (PR-L).

    Time frame: up to 3.5 years

  5. Number of Participants Experiencing Adverse Events (AEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. All AEs were monitored per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE version \[v\] 4.03 2010). A treatment emergent adverse event (TEAE) is defined as an adverse event that has an onset date or a worsening in severity from baseline (pretreatment) on or after the date of first dose of study drug up to 30 days following study drug discontinuation or initiation of new anticancer therapy, whichever occurs first.

    Time frame: Up to 3.5 years

08

Results

Posted Sep 25, 2020

Participant flow

91 participants were enrolled at 11 sites in China. The first participant was dosed on 09 March 2017. Database lock date for the primary outcome measure was 14 December 2018. Final database lock date was 16 October 2020.

Participant flow — Overall Study
MilestoneZanubrutinib
Started91
Completed0
Not completed91
Withdrew: Death11
Withdrew: Withdrawal by subject5
Withdrew: Study terminated by sponsor12
Withdrew: Lost to follow-up3
Withdrew: Transferred to extension study bgb-3111-lte1 (nct04170283)60

Outcome measures

PrimaryOverall Response Rate (ORR) by Independent Review Committee (IRC)

ORR is defined as the number of participants who achieve a best response of CR or, CRi, Nodular Partial Response, PR, and PR with Lymphocytosis as assessed by IRC per the modified IWCLL Guidelines in participants with CLL and the Revised Criteria for Response for Malignant Lymphoma in participants with SLL.

Time frame:
Up to 1 year and 4 months
Reported as:
Count of participants · Participants
Overall Response Rate (ORR) by Independent Review Committee (IRC)
ParticipantsZanubrutinib
Overall Response Rate (ORR) by Independent Review Committee (IRC)80
Statistical analysis
  • Zanubrutinib · Exact Binomial Test · p = <0.0001 · 2-side clopper-pearson: 87.9 · 95% CI 79.40 to 93.81The null hypothesis is ORR = 32%
SecondaryProgression-free Survival (PFS): Percentage of Participants Progression/Death Event Free

PFS is defined as the time from treatment initiation to first documentation of progression by International workshop on chronic lymphocytic leukemia (IWCLL) criteria/revised criteria for response for malignant lymphoma or death, whichever is earlier.

Time frame:
6, 12, 24, and 36 months
Reported as:
Median · Percentage of participants
Progression-free Survival (PFS): Percentage of Participants Progression/Death Event Free
Percentage of participantsZanubrutinib
6 months93.3 (85.72 to 96.94)
12 months88.7 (80.04 to 93.77)
24 months80.5 (70.52 to 87.42)
36 months68.1 (56.56 to 77.24)
SecondaryDuration of Response (DOR): Event Free Rate - Percentage of Participants Who Remained Event Free

DOR is defined as the time from the date that response criteria are first met to the date that progressive disease (PD) is objectively documented or death, whichever occurs first

Time frame:
6, 12, 24, and 36 months
Reported as:
Median · Percentage of participants
Duration of Response (DOR): Event Free Rate - Percentage of Participants Who Remained Event Free
Percentage of participantsZanubrutinib
6 Months97.5 (90.37 to 99.37)
12 Months92.5 (83.96 to 96.54)
24 Months83.4 (73.20 to 90.04)
36 Months69.9 (57.02 to 79.55)
SecondaryTime to Response (TTR)

TTR is defined as the time from treatment initiation to first signs of response

Time frame:
Up to 3.5 years
Reported as:
Median · Months
Time to Response (TTR)
MonthsZanubrutinib
Time to Response (TTR)2.79 (2.6 to 16.8)
SecondaryOverall Response Rate as Determined by the Investigator

Overall response was defined as achieving a best overall response of CR, CRi, nodular partial response (nPR), PR, or partial response with lymphocytosis (PR-L).

Time frame:
up to 3.5 years
Reported as:
Median · Percentage of participants
Overall Response Rate as Determined by the Investigator
Percentage of participantsZanubrutinib
Overall Response Rate as Determined by the Investigator92.3 (84.79 to 96.85)
SecondaryNumber of Participants Experiencing Adverse Events (AEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. All AEs were monitored per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE version \[v\] 4.03 2010). A treatment emergent adverse event (TEAE) is defined as an adverse event that has an onset date or a worsening in severity from baseline (pretreatment) on or after the date of first dose of study drug up to 30 days following study drug discontinuation or initiation of new anticancer therapy, whichever occurs first.

Time frame:
Up to 3.5 years
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs)
ParticipantsZanubrutinib
At Least 1 TEAE91
Grade 3 or higher TEAE76
Serious TEAEs47
TEAE leading to death6
TEAE leading to treatment discontinuation14
TEAE leading to treatment modification42
TEAE leading to treatment interruption42
TEAE leading to dose reduction8
Treatment-related TEAE90

Adverse events

Collected over Up to 3.5 years. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zanubrutinib11/91 (12.1%)47/91 (51.6%)91/91 (100%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventZanubrutinib
PneumoniaInfections and infestations22/91
Lung infectionInfections and infestations7/91
Upper respiratory tract infectionInfections and infestations4/91
BronchitisInfections and infestations3/91
Hepatitis BInfections and infestations3/91
GastroenteritisInfections and infestations2/91
Skin infectionInfections and infestations2/91
HeadacheNervous system disorders2/91
Adenocarcinoma gastricNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/91
AnaemiaBlood and lymphatic system disorders1/91
Most frequent other events
Showing 10 of 106
Most frequent other events
EventZanubrutinib
Neutrophil count decreasedInvestigations70/91
Upper respiratory tract infectionInfections and infestations50/91
HaematuriaRenal and urinary disorders40/91
Platelet count decreasedInvestigations39/91
AnaemiaBlood and lymphatic system disorders32/91
PurpuraSkin and subcutaneous tissue disorders31/91
HypokalaemiaMetabolism and nutrition disorders28/91
CoughRespiratory, thoracic and mediastinal disorders27/91
HyperglycaemiaMetabolism and nutrition disorders26/91
PneumoniaInfections and infestations24/91

Baseline characteristics

Safety Analysis Set: All participants who received any dose of study drug.

Age, Continuous
Age, Continuous(years)Zanubrutinib
Mean60.9 ± 9.73
Age, Customized
Age, Customized(Participants)Zanubrutinib
<6560
≥6531
Sex: Female, Male
Sex: Female, Male(Participants)Zanubrutinib
Female39
Male52
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Zanubrutinib
Chinese91
Other0
09

Study locations

11 sites
  • Peking University Peoples Hospital
    Beijing, Beijing 100044, China
  • Peking Union Medical College Hospital
    Beijing, Beijing 100730, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Institute of Hematology and Hospital of Blood Disease
    Tianjin, Tianjin 300020, China
10

References and documents

Publications

  • Xu W, Yang S, Zhou K, Pan L, Li Z, Zhou J, Gao S, Zhou D, Hu J, Feng R, Huang H, Ji M, Guo H, Huang J, Novotny W, Feng S, Li J. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. J Hematol Oncol. 2020 May 11;13(1):48. doi: 10.1186/s13045-020-00884-4. PubMed 32393328 ↗
  • Xu W, Yang S, Tam CS, Seymour JF, Zhou K, Opat S, Qiu L, Sun M, Wang T, Trotman J, Pan L, Gao S, Zhou J, Zhou D, Zhu J, Song Y, Hu J, Feng R, Huang H, Su D, Shi M, Li J. Zanubrutinib Monotherapy for Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies. Adv Ther. 2022 Sep;39(9):4250-4265. doi: 10.1007/s12325-022-02238-7. Epub 2022 Jul 28. PubMed 35900694 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Jun 2018, 15 months.

Results were first posted in Sep 2020, 2 years 3 months after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 15 months is below that.

Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2017
First posted
Jul 2, 2017
StartActual
Mar 9, 2017
Primary completionActual
Jun 15, 2018
CompletionActual
Sep 10, 2020
Results first posted
Sep 25, 2020
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03206918
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Jul 2, 2017
Start date
Mar 9, 2017
Primary completion
Jun 15, 2018
Completion
Sep 10, 2020
Results posted
Sep 25, 2020
Last update
Oct 26, 2024

Study contacts

Study Director
principal investigator · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion